Patents Assigned to Aegis Therapeutics, LLC
  • Intranasal epinephrine formulations and methods for the treatment of disease
    Patent number: 11918655
    Abstract: Drug products adapted for nasal delivery comprising formulations with epinephrine and devices comprising such formulations are provided. Methods of treating anaphylaxis with epinephrine products are also provided.
    Type: Grant
    Filed: June 7, 2023
    Date of Patent: March 5, 2024
    Assignee: AEGIS THERAPEUTICS, LLC
    Inventors: Richard Lowenthal, Edward T. Maggio, Robert G. Bell, Pratik Shah
  • Intranasal epinephrine formulations and methods for the treatment of disease
    Patent number: 11744895
    Abstract: Drug products adapted for nasal delivery comprising formulations with epinephrine and devices comprising such formulations are provided. Methods of treating anaphylaxis with epinephrine products are also provided.
    Type: Grant
    Filed: August 6, 2021
    Date of Patent: September 5, 2023
    Assignee: AEGIS THERAPEUTICS, LLC
    Inventors: Richard Lowenthal, Edward T. Maggio, Robert G. Bell, Pratik Shah
  • Intranasal epinephrine formulations and methods for the treatment of disease
    Patent number: 11717571
    Abstract: Drug products adapted for nasal delivery comprising formulations with epinephrine and devices comprising such formulations are provided. Methods of treating anaphylaxis with epinephrine products are also provided.
    Type: Grant
    Filed: October 26, 2022
    Date of Patent: August 8, 2023
    Assignee: AEGIS THERAPEUTICS, LLC
    Inventors: Richard Lowenthal, Edward T. Maggio, Robert G. Bell, Pratik Shah
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPIOID OVERDOSE
    Publication number: 20220387306
    Abstract: Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising nalmefene are provided. Methods of treating opioid overdose with the drug products are also provided.
    Type: Application
    Filed: August 4, 2022
    Publication date: December 8, 2022
    Applicants: Opiant Pharmaceuticals, Inc., Aegis Therapeutics, LLC
    Inventors: Roger CRYSTAL, Edward T. MAGGIO
  • Compositions and methods for the treatment of opioid overdose
    Patent number: 11458091
    Abstract: Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising nalmefene are provided. Methods of treating opioid overdose with the drug products are also provided.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: October 4, 2022
    Assignees: Opiant Pharmaceuticals, Inc., Aegis Therapeutics, LLC
    Inventors: Roger Crystal, Edward T. Maggio
  • Intranasal epinephrine formulations and methods for the treatment of disease
    Patent number: 11191838
    Abstract: Drug products adapted for nasal delivery comprising formulations with epinephrine and devices comprising such formulations are provided. Methods of treating anaphylaxis with epinephrine products are also provided.
    Type: Grant
    Filed: May 7, 2020
    Date of Patent: December 7, 2021
    Assignee: AEGIS THERAPEUTICS, LLC
    Inventors: Richard Lowenthal, Edward T. Maggio, Robert G. Bell, Pratik Shah
  • Compositions for drug administration
    Patent number: 11173209
    Abstract: The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: November 16, 2021
    Assignee: AEGIS THERAPEUTICS, LLC
    Inventor: Edward T. Maggio
  • Intranasal epinephrine formulations and methods for the treatment of disease
    Patent number: 10682414
    Abstract: Drug products adapted for nasal delivery comprising formulations with epinephrine and devices comprising such formulations are provided. Methods of treating anaphylaxis with epinephrine products are also provided.
    Type: Grant
    Filed: May 22, 2019
    Date of Patent: June 16, 2020
    Assignee: AEGIS THERAPEUTICS, LLC
    Inventors: Richard Lowenthal, Edward T. Maggio, Robert G. Bell, Pratik Shah
  • Compositions for drug administration
    Patent number: 10576156
    Abstract: The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms.
    Type: Grant
    Filed: February 6, 2018
    Date of Patent: March 3, 2020
    Assignee: Aegis Therapeutics, LLC
    Inventor: Edward T. Maggio
  • Compositions for oral drug administration
    Patent number: 10512694
    Abstract: The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms. In various aspects, the invention provides compositions and methods for oral delivery in the form of a tablet.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: December 24, 2019
    Assignee: Aegis Therapeutics, LLC
    Inventor: Edward T. Maggio
  • Absorption enhancers for drug administration
    Patent number: 10265402
    Abstract: The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms. In various aspects, the invention provides compositions and methods for oral delivery in the form of a tablet.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: April 23, 2019
    Assignee: Aegis Therapeutics, LLC
    Inventor: Edward T. Maggio
  • Stabilizing alkylglycoside compositions and methods thereof
    Patent number: 10046025
    Abstract: The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a cyclic polypeptide.
    Type: Grant
    Filed: September 13, 2016
    Date of Patent: August 14, 2018
    Assignee: Aegis Therapeutics, LLC
    Inventor: Edward T. Maggio
  • Compositions for drug administration
    Patent number: 9895444
    Abstract: The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: February 20, 2018
    Assignee: Aegis Therapeutics, LLC
    Inventor: Edward T. Maggio
  • Pharmaceutical composition including alkyl glycoside and an anti-seizure agent
    Patent number: 9642913
    Abstract: A composition including a surfactant and at least one alkyl glycoside and/or saccharide alkyl ester and a drug. The surfactant composition(s) when admixed with a drug is non-toxic and non-irritating, while stabilizing and increasing the bioavailability of the drug. The invention also provides compositions that enhance absorption of drugs via the oral, ocular, nasal, nasolacrimal, inhalation or pulmonary, oral cavity (sublingual or Buccal cell) or CSF delivery route of a patient, including but not limited to insulin, glucagon and exendin-4.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: May 9, 2017
    Assignee: Aegis Therapeutics, LLC.
    Inventor: Edward T. Maggio
  • Stabilizing alkylglycoside compositions and methods thereof
    Patent number: 9446134
    Abstract: The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or variant thereof, for example octreotide or variant thereof.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: September 20, 2016
    Assignee: Aegis Therapeutics, LLC
    Inventor: Edward T. Maggio
  • Compositions for drug administration
    Patent number: 9283280
    Abstract: The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject, as well as compositions and methods for providing migraine pain relief. The compositions include at least one alkyl glycoside and at least one therapeutic agent, such as a 5-HT receptor agonist, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms.
    Type: Grant
    Filed: May 13, 2013
    Date of Patent: March 15, 2016
    Assignee: Aegis Therapeutics, LLC
    Inventor: Edward T. Maggio
  • Antibacterial compositions for drug administration
    Patent number: 9114069
    Abstract: Non-toxic aqueous compositions are provided having antibacterial activity. Specifically, the invention provides aqueous alkyl glycoside or saccharide alkyl ester compositions which meet the antimicrobial effectiveness test criteria set forth in USP 31 <51> in preventing growth of specified bacteria and fungi.
    Type: Grant
    Filed: July 30, 2009
    Date of Patent: August 25, 2015
    Assignee: Aegis Therapeutics, LLC
    Inventor: Edward T. Maggio
  • Absorption enhancers for intranasal administration
    Patent number: 8927497
    Abstract: A composition including a surfactant and at least one alkyl glycoside and/or saccharide alkyl ester and a drug. The surfactant composition(s) when admixed with a drug is non-toxic and non-irritating, while stabilizing and increasing the bioavailability of the drug. The invention also provides compositions that enhance absorption of drugs via the oral, ocular, nasal, nasolacrimal, inhalation or pulmonary, oral cavity (sublingual or Buccal cell) or CSF delivery route of a patient, including but not limited to insulin, glucagon and exendin-4.
    Type: Grant
    Filed: February 10, 2012
    Date of Patent: January 6, 2015
    Assignee: Aegis Therapeutics, LLC.
    Inventor: Edward T. Maggio
  • Intranasal administration of active agents to the central nervous system
    Patent number: 8883728
    Abstract: Pharmaceutical compositions and methods for delivering a polypeptide to the central nervous system of a mammal via intranasal administration are provided. The polypeptide can be a catalytically active protein or an antibody, antibody fragment or antibody fragment fusion protein. The polypeptides are formulated with one or more specific agents.
    Type: Grant
    Filed: November 24, 2010
    Date of Patent: November 11, 2014
    Assignee: Aegis Therapeutics, LLC
    Inventor: Edward T. Maggio
  • Stabilizing alkylglycoside compositions and methods thereof
    Patent number: 8846044
    Abstract: The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or variant thereof, for example parathyroid hormone (PTH) or PTH analogs, amylin, a monoclonal antibody, insulin, Peptide T or analog thereof, gastrin, gastrin releasing peptides, gastrin releasing peptide-like (GRP) proteins, epidermal growth factor or analog thereof.
    Type: Grant
    Filed: July 9, 2012
    Date of Patent: September 30, 2014
    Assignee: Aegis Therapeutics, LLC
    Inventor: Edward T. Maggio